# ILIAS Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ilias-biologics

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.iliasbio.com
- Total disclosed funding: $37M
- Latest round: Series B (Sep 26, 2020)
- Investors on record: 16

## About

Founded in 2015 and based in Daejeon, South Korea, ILIAS Biologics Inc. is a biotechnology company that focuses on developing therapeutic molecules as potential treatments for sepsis, pre-term birth, and various hard-to-treat diseases in inflammatory and metabolic areas.

## Funding rounds

- Series B, Sep 26, 2020, $21M — Meritz Securities, HB Investment, Kiwoom Securities, Time Folio Asset Management, Daishin Securities, Devsisters Ventures, Daedeok Venture Partners, YEOLLIM Partners, Hanyang Securities, Cenit Co., Ltd., Genie Asset Management
- Series A, Jun 19, 2018, $17M — InterVest, WOORI Venture Partners, Shinhan Securities, HB Investment, SV Investment, Samsung Securities, Time Folio Asset Management, Daedeok Venture Partners

## Investors

- InterVest (https://capitalatlas.ai/funds/intervest) — Series A
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series A
- Shinhan Securities (https://capitalatlas.ai/funds/shinhan-securities) — Series A
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series A, Series B
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series A
- Samsung Securities — Series A
- Time Folio Asset Management — Series A, Series B
- Daedeok Venture Partners (https://capitalatlas.ai/funds/daedeok-venture-partners) — Series A, Series B
- Meritz Securities — Series B
- Kiwoom Securities — Series B
- Daishin Securities — Series B
- Devsisters Ventures (https://capitalatlas.ai/funds/devsisters-ventures) — Series B
- YEOLLIM Partners — Series B
- Hanyang Securities — Series B
- Cenit Co., Ltd. — Series B
- Genie Asset Management — Series B